Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

NLK is a novel therapeutic target for PTEN deficient tumour cells.

Mendes-Pereira AM, Lord CJ, Ashworth A.

PLoS One. 2012;7(10):e47249. doi: 10.1371/journal.pone.0047249. Epub 2012 Oct 29.

2.

FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment.

Ma Q, Fu W, Li P, Nicosia SV, Jenster G, Zhang X, Bai W.

Mol Endocrinol. 2009 Feb;23(2):213-25. doi: 10.1210/me.2008-0147. Epub 2008 Dec 12.

3.

Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase.

Mereniuk TR, El Gendy MA, Mendes-Pereira AM, Lord CJ, Ghosh S, Foley E, Ashworth A, Weinfeld M.

Mol Cancer Ther. 2013 Oct;12(10):2135-44. doi: 10.1158/1535-7163.MCT-12-1093. Epub 2013 Jul 24.

4.

PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.

Guigon CJ, Zhao L, Willingham MC, Cheng SY.

Oncogene. 2009 Jan 29;28(4):509-17. doi: 10.1038/onc.2008.407. Epub 2008 Nov 10.

5.

A high-throughput screen with isogenic PTEN+/+ and PTEN-/- cells identifies CID1340132 as a novel compound that induces apoptosis in PTEN and PIK3CA mutant human cancer cells.

Li HF, Keeton A, Vitolo M, Maddox C, Rasmussen L, Hobrath J, White EL, Park BH, Piazza GA, Kim JS, Waldman T.

J Biomol Screen. 2011 Apr;16(4):383-93. doi: 10.1177/1087057110397357. Epub 2011 Feb 18.

6.

FOXO1/3 and PTEN Depletion in Granulosa Cells Promotes Ovarian Granulosa Cell Tumor Development.

Liu Z, Ren YA, Pangas SA, Adams J, Zhou W, Castrillon DH, Wilhelm D, Richards JS.

Mol Endocrinol. 2015 Jul;29(7):1006-24. doi: 10.1210/me.2015-1103. Epub 2015 Jun 10.

7.

PTEN-mediated Akt/╬▓-catenin/Foxo1 signaling regulates innate immune responses in mouse liver ischemia/reperfusion injury.

Kamo N, Ke B, Busuttil RW, Kupiec-Weglinski JW.

Hepatology. 2013 Jan;57(1):289-98. doi: 10.1002/hep.25958. Epub 2012 Dec 4.

8.

Involvement of the PTEN-AKT-FOXO3a pathway in neuronal apoptosis in developing rat brain after hypoxia-ischemia.

Li D, Qu Y, Mao M, Zhang X, Li J, Ferriero D, Mu D.

J Cereb Blood Flow Metab. 2009 Dec;29(12):1903-13. doi: 10.1038/jcbfm.2009.102. Epub 2009 Jul 22.

9.

Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer.

Wu Z, He B, He J, Mao X.

Prostate. 2013 May;73(6):596-604. doi: 10.1002/pros.22600. Epub 2012 Oct 11.

PMID:
23060044
10.

PTEN-regulated AKT/FoxO3a/Bim signaling contributes to reactive oxygen species-mediated apoptosis in selenite-treated colorectal cancer cells.

Luo H, Yang Y, Duan J, Wu P, Jiang Q, Xu C.

Cell Death Dis. 2013 Feb 7;4:e481. doi: 10.1038/cddis.2013.3.

11.

MiR-101 functions as a tumor suppressor by directly targeting nemo-like kinase in liver cancer.

Shen Q, Bae HJ, Eun JW, Kim HS, Park SJ, Shin WC, Lee EK, Park S, Park WS, Lee JY, Nam SW.

Cancer Lett. 2014 Mar 28;344(2):204-11. doi: 10.1016/j.canlet.2013.10.030. Epub 2013 Nov 1.

PMID:
24189458
12.

Rescue of glandular dysmorphogenesis in PTEN-deficient colorectal cancer epithelium by PPAR╬│-targeted therapy.

Jagan I, Fatehullah A, Deevi RK, Bingham V, Campbell FC.

Oncogene. 2013 Mar 7;32(10):1305-15. doi: 10.1038/onc.2012.140. Epub 2012 Apr 30.

13.

A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours.

Kalathur M, Toso A, Chen J, Revandkar A, Danzer-Baltzer C, Guccini I, Alajati A, Sarti M, Pinton S, Brambilla L, Di Mitri D, Carbone G, Garcia-Escudero R, Padova A, Magnoni L, Tarditi A, Maccari L, Malusa F, Kalathur RK, A Pinna L, Cozza G, Ruzzene M, Delaleu N, Catapano CV, Frew IJ, Alimonti A.

Nat Commun. 2015 Jun 18;6:7227. doi: 10.1038/ncomms8227.

PMID:
26085373
14.
15.

A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells.

Liu P, Li S, Gan L, Kao TP, Huang H.

Cancer Res. 2008 Dec 15;68(24):10290-9. doi: 10.1158/0008-5472.CAN-08-2038.

16.

Therapeutic targeting of cancers with loss of PTEN function.

Dillon LM, Miller TW.

Curr Drug Targets. 2014 Jan;15(1):65-79.

17.

Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.

Maxwell PJ, Coulter J, Walker SM, McKechnie M, Neisen J, McCabe N, Kennedy RD, Salto-Tellez M, Albanese C, Waugh DJ.

Eur Urol. 2013 Aug;64(2):177-88. doi: 10.1016/j.eururo.2012.08.032. Epub 2012 Aug 28.

18.

Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.

Zhao Y, Wang Z, Jiang Y, Yang C.

Cancer Lett. 2011 Dec 26;313(1):54-63. doi: 10.1016/j.canlet.2011.08.023. Epub 2011 Sep 3.

PMID:
21943825
19.

miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer.

Cai J, Fang L, Huang Y, Li R, Yuan J, Yang Y, Zhu X, Chen B, Wu J, Li M.

Cancer Res. 2013 Sep 1;73(17):5402-15. doi: 10.1158/0008-5472.CAN-13-0297. Epub 2013 Jul 15.

20.

PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation.

Lee JJ, Kim BC, Park MJ, Lee YS, Kim YN, Lee BL, Lee JS.

Cell Death Differ. 2011 Apr;18(4):666-77. doi: 10.1038/cdd.2010.139. Epub 2010 Nov 12.

Items per page

Supplemental Content

Write to the Help Desk